Table 2 Outcome from prospective trials... | American Society of Hematology

Table 2

Outcome from prospective trials designed for older ALL patients

Reference	Year	Age (range) (y)	Ph+	No. of patients	CR rate (%)	Early death (%)	Failure (%)	CCR*		DFS*	OS†
Reference	Year	Age (range) (y)	Ph+	No. of patients	CR rate (%)	Early death (%)	Failure (%)	%	Years	DFS*	%	Years
Bassan et al⁵¹	1996	64 (60-73)	Yes	22	59	18	14	12		9	20	2
Delannoy et al⁵²	1997	67 (55-86)	Yes	40	85	N/R	N/R	N/R		14	16	2
Delannoy et al⁶⁴	2002	65 (55-81)	Yes	58	43	10	47	5		10	N/R
Offidani et al¹⁴	2004	69 (61-79)	Yes	17	76	17	6	20		21	38	2
Sancho et al⁵³	2007	65 (56-77)	No	33	58	36	6	46	2	7	39	1
Kao et al⁵⁴	2008	66 (60-78)	Yes	17	71	29	0	82	1	N/R	71	1
Gökbuget et al⁵⁵	2008	66 (56-73)	No	54	85	0	15	9		N/R	61	1
Hunault-Berger et al⁵⁶	2010
Arm 1		68 (55-77)	No	31	90	7	3	32	2	N/R	35	2
Arm 2		66 (60-80)		29	72	10	17	52	2		24	2
Gökbuget et al²⁸	2012	57 (55-85)	No	268	76	14	10	32	5	N/R	23	5

Reference	Year	Age (range) (y)	Ph+	No. of patients	CR rate (%)	Early death (%)	Failure (%)	CCR*		DFS*	OS†
Reference	Year	Age (range) (y)	Ph+	No. of patients	CR rate (%)	Early death (%)	Failure (%)	%	Years	DFS*	%	Years
Bassan et al⁵¹	1996	64 (60-73)	Yes	22	59	18	14	12		9	20	2
Delannoy et al⁵²	1997	67 (55-86)	Yes	40	85	N/R	N/R	N/R		14	16	2
Delannoy et al⁶⁴	2002	65 (55-81)	Yes	58	43	10	47	5		10	N/R
Offidani et al¹⁴	2004	69 (61-79)	Yes	17	76	17	6	20		21	38	2
Sancho et al⁵³	2007	65 (56-77)	No	33	58	36	6	46	2	7	39	1
Kao et al⁵⁴	2008	66 (60-78)	Yes	17	71	29	0	82	1	N/R	71	1
Gökbuget et al⁵⁵	2008	66 (56-73)	No	54	85	0	15	9		N/R	61	1
Hunault-Berger et al⁵⁶	2010
Arm 1		68 (55-77)	No	31	90	7	3	32	2	N/R	35	2
Arm 2		66 (60-80)		29	72	10	17	52	2		24	2
Gökbuget et al²⁸	2012	57 (55-85)	No	268	76	14	10	32	5	N/R	23	5

Ph+, Ph/BCR-ABL–positive ALL included; Arm 1, continuous infusion doxorubicine; Arm 2, pegylated doxorubicine.

CCR, continuous complete remission; DFS, disease-free survival; OS, overall survival.

Median months or probability.

Probability.